GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PolyPid Ltd (NAS:PYPD) » Definitions » Long-Term Capital Lease Obligation

PYPD (PolyPid) Long-Term Capital Lease Obligation : $1.04 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is PolyPid Long-Term Capital Lease Obligation?

PolyPid's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was $1.04 Mil.

PolyPid's quarterly Long-Term Capital Lease Obligation declined from Sep. 2024 ($1.42 Mil) to Dec. 2024 ($1.28 Mil) and declined from Dec. 2024 ($1.28 Mil) to Mar. 2025 ($1.04 Mil).

PolyPid's annual Long-Term Capital Lease Obligation declined from Dec. 2022 ($1.17 Mil) to Dec. 2023 ($0.86 Mil) but then increased from Dec. 2023 ($0.86 Mil) to Dec. 2024 ($1.28 Mil).


PolyPid Long-Term Capital Lease Obligation Historical Data

The historical data trend for PolyPid's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPid Long-Term Capital Lease Obligation Chart

PolyPid Annual Data
Trend Dec13 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.17 0.86 1.28

PolyPid Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.82 1.59 1.42 1.28 1.04

PolyPid  (NAS:PYPD) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

PolyPid Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of PolyPid's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


PolyPid Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PolyPid Ltd (NAS:PYPD) » Definitions » Long-Term Capital Lease Obligation
Traded in Other Exchanges
N/A
Address
18 Hasivim Street, P.O Box 7126, Petach Tikva, ISR, 495376
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.